Advertisement

Release of Catecholamines, Serotonin, and Acetylcholine from Isolated Brain Tissue

  • Maurizio Raiteri
  • Mario Marchi
  • Guido Maura

Abstract

Release of transmitter substances is a fundamental step of chemical neuro-transmission that occurs in the living brain, under physiological conditions, when presynaptic nerve endings are invaded by an action potential.5 The available evidence suggests that in vivo the release process is intimately connected with many other steps of neurotransmission including supply of transmitter precursors, transmitter synthesis, compartmentation, reuptake, and catabo-lism. The release of several transmitters appears to be under the control of specific feedback mechanisms mediated by receptors localized on presynaptic nerve terminals. Moreover, the release of one transmitter can be regulated by other transmitters or modulators through receptor-mediated interactions varying among different brain regions. Neuro- and psychoactive drugs can interfere, at various levels, with neurotransmitter release.

Keywords

Nerve Terminal Biogenic Amine Nerve Ending Brain Slice Transmitter Release 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Baldessarini, R. J., 1975, Handbook of Psychopharmacology ,Volume 3, Biochemistry of Biogenic Amines (L. L. Iversen, S. D. Iversen, and S. H. Snyder, eds.), Plenum Press, New York, pp. 37–137.Google Scholar
  2. 2.
    Raiteri, M., and Levi, G., 1978, Reviews of Neurosciences ,Volume 3 (S. Ehrenpreis and I. Kopin, eds.), Raven Press, New York, pp. 77–130.Google Scholar
  3. 3.
    Paton, D. M. (ed.), 1979, The Release of Catecholamines from Adrenergic Neurons ,Pergamon Press, Oxford.Google Scholar
  4. 4.
    Kelly, R. B., Deutsch, J. W., Carlson, S. S., and Wagner, J. A., 1979, Annu. Rev. Neurosci. 2:399–446.PubMedGoogle Scholar
  5. 5.
    Yamamoto, C., and Mcllwain, H., 1966, J. Neurochem. 13:1333–1343.PubMedGoogle Scholar
  6. 6.
    Raiteri, M., Angelini, F., and Levi, G., 1974, Eur. J. Pharmacol. 25:411–414.PubMedGoogle Scholar
  7. 7.
    Iversen, L. L., 1970, Advances in Biochemical Psychopharmacology ,Volume 2, Biochemistry of Simple Neuronal Models (E. Costa and E. Giacobini, eds.), Raven Press, New York, pp. 109–132.Google Scholar
  8. 8.
    Iversen, L. L., 1974, Biochem. Pharmacol. 23:1927–1935.PubMedGoogle Scholar
  9. 9.
    Kuhar, M. J., and Murrin, L. C., 1978, J. Neurochem. 30:15–21.PubMedGoogle Scholar
  10. 10.
    Lane, J. D., and Aprison, M. H., 1977, Life Sci. 20:665–672.PubMedGoogle Scholar
  11. 11.
    Reubi, J. C., and Emson, P. C., 1978, Brain Res. 139:164–168.PubMedGoogle Scholar
  12. 12.
    Hamlet, M. A., Rorie, D. K., and Tyce, G. M., 1981, Brain Res. 217:315–325.PubMedGoogle Scholar
  13. 13.
    Wightman, R. M., Bright, C. E., and Caviness, J. N., 1981, Life Sci. 28:1279–1286.PubMedGoogle Scholar
  14. 14.
    Moroni, F., Bianchi, C., Tanganelli, S., Moneti, G., and Beani, L., 1981, J. Neurochem. 36:1691–1697.PubMedGoogle Scholar
  15. 15.
    Vizi, E. S., Harsing, L. G., and Zsilla, G., 1981, Brain Res. 212:89–99.PubMedGoogle Scholar
  16. 16.
    Mefford, I. N., 1981, J. Neurosci. Methods 3:207–224.PubMedGoogle Scholar
  17. 17.
    Israel, M., and Lesbats, B., 1981, Neurochem. Int. 3:81–90.PubMedGoogle Scholar
  18. 18.
    Trendelenburg, U., 1979, The Release of Catecholamines from Adrenergic Neurons (D. M. Paton ed.), Pergamon Press, Oxford, pp. 333–354.Google Scholar
  19. 19.
    Haycock, J. W., and Meligeni, J. A., 1977, Life Sci. 21:1837–1844.PubMedGoogle Scholar
  20. 20.
    Raiteri, M., Bertollini, A., Angelini, F., and Levi, G., 1975, Eur. J. Pharmacol. 34:189–195.PubMedGoogle Scholar
  21. 21.
    Kuhar, M. J., Sethy, V. H., Roth, R. H., and Aghajanian, G. K., 1973,7. Neurochem. 20:581–593.Google Scholar
  22. 22.
    Guyenet, P., Lefresne, P., Rossier, J., Beaujouan, J. C., and Glowinski, J., 1973, Mol. Pharmacol. 9:630–639.PubMedGoogle Scholar
  23. 23.
    Annunziato, L., Leblanc, P., Kordon, C., and Weiner, R. I., 1980, Neuroendocrinology 31:316–320.PubMedGoogle Scholar
  24. 24.
    Ross, S. B., Ogren, S. O., and Renyi, A. L., 1976, Acta Pharmacol. Toxicol. (Kbh.) 39:152–166.Google Scholar
  25. 25.
    Waldmeier, P. C., Baumann, P. A., Wilhelm, M., Bernasconi, R., and Maître, L., 1977, Eur. J. Pharmacol. 46:387–391.PubMedGoogle Scholar
  26. 26.
    Wong, D. T., and Bymaster, F. P., 1978, Life Sci. 23:1041–1048.PubMedGoogle Scholar
  27. 27.
    Van der Zee, P., Koger, H. S., Gootjes, J., and Hespe, W., 1980, Eur. J. Med. Chem. 15:363–370.Google Scholar
  28. 28.
    Fuller, R. W., 1980, Annu. Rev. Pharmacol. Toxicol. 20:111–127.PubMedGoogle Scholar
  29. 29.
    Giorguieff, M. F., Le Floc’h, M. L., Glowinski, J., and Besson, M. J., 1977, J. Pharmacol. Exp. Ther. 200:535–544.PubMedGoogle Scholar
  30. 30.
    Nordström, O., and Bartfai, T., 1980, Acta Physiol. Scand. 108:347–353.PubMedGoogle Scholar
  31. 31.
    Cerrito, F., and Raiteri, M., 1979, Eur. J. Pharmacol. 57:427–430.PubMedGoogle Scholar
  32. 32.
    Raiteri, M., del Carmine, R., Bertollini, A., and Levi, G., 1977, Mol. Pharmacol. 13:746–758.PubMedGoogle Scholar
  33. 33.
    Raiteri, M., Cerrito, F., Cervoni, A. M., and Levi, G., 1979, J. Pharmacol. Exp. Ther. 208:195–202.PubMedGoogle Scholar
  34. 34.
    Maura, G., Gemignani, A., Versace, P., Martire, M., and Raiteri, M., 1982, Neurochem. Int. 4:219–224.PubMedGoogle Scholar
  35. 35.
    Paton, D. M., 1979, The Release of Catecholamines from Adrenergic Neurons (D. M. Paton, ed.), Pergamon Press, Oxford, pp. 323–332.Google Scholar
  36. 36.
    Orrego, F., 1979, Neuroscience 4:1037–1057.PubMedGoogle Scholar
  37. 37.
    Dismukes, K., de Boer, A. A., and Mulder, A. H., 1977, Naunyn-Schmiedeberg s Arch. Pharmacol. 299:115–122.Google Scholar
  38. 38.
    Starke, K., and Montel, H., 1973, Neuropharmacologia 12:1073–1080.Google Scholar
  39. 39.
    Blaustein, M. P., 1975, J. Physiol. (Lond.) 247:617–655.Google Scholar
  40. 40.
    Schoffelmeer, A. N. M., Werner, J., and Mulder, A. H., 1981, Neurochem. Int. 3:129–136.PubMedGoogle Scholar
  41. 41.
    Starke, K., 1981, Annu. Rev. Pharmacol. Toxicol. 21:7–30.PubMedGoogle Scholar
  42. 42.
    Goddard, G. A., and Robinson, J. D., 1976, Brain Res. 110:331–350.PubMedGoogle Scholar
  43. 43.
    Levi, G., Gallo, V., and Raiteri, M., 1980, Neurochem. Res. 5:281–295.PubMedGoogle Scholar
  44. 44.
    Raiteri, M., Federico, R., Coletti, A., and Levi, G., 1975, J. Neurochem. 24:1243–1250.PubMedGoogle Scholar
  45. 45.
    Marchi, M., Paudice, P., and Raiteri, M., 1981, Eur. J. Pharmacol. 73:75–79.PubMedGoogle Scholar
  46. 46.
    Nordström, O., Westlind, A., Hedlund, B., Unden, A., and Bartfai, T., 1981, Cholinergic Mechanisms: Phylogenetic Aspects, Central and Peripheral Synapses and Clinical Signifi cance (G. Pepeu and H. Ladinsky, eds.), Plenum Press, New York, pp. 579–586.Google Scholar
  47. 47.
    Luqmani, Y. A., Bradford, H. F., Birdsall, N. J. M., and Hulme, E. C., 1979, Nature 277:481–483.PubMedGoogle Scholar
  48. 48.
    Blaustein, M. P., 1979, The Release of Catecholamines from Adrenergic Neurons (D. M. Paton ed.), Pergamon Press, Oxford, pp. 39–58.Google Scholar
  49. 49.
    Hagiwara, S., and Byerly, L., 1981, Annu. Rev. Neurosci. 4:69–125.PubMedGoogle Scholar
  50. 50.
    Nachshen, D. A., and Blaustein, M. P., 1980, J. Gen. Physiol. 76:709–728.PubMedGoogle Scholar
  51. 51.
    Henry, P. D., 1980, Am. J. Cardiol. 46:1047–1057.PubMedGoogle Scholar
  52. 52.
    Blaustein, M. P., and Hector, C. A., 1975, Mol. Pharmacol. 11:369–378.PubMedGoogle Scholar
  53. 53.
    Brehm, P., and Eckert, R., 1978, Science 202:1203–1206.PubMedGoogle Scholar
  54. 54.
    Katz, B., and Miledi, R., 1970, J. Physiol. (Lond.) 207:789–801.Google Scholar
  55. 55.
    Pressman, B. C., 1976, Annu. Rev. Biochem. 45:501–530.PubMedGoogle Scholar
  56. 56.
    Triggle, D. J., 1979, The Release of Catecholamines from Adrenergic Neurons (D. M. Paton ed.), Pergamon Press, Oxford, pp. 303–322.Google Scholar
  57. 57.
    Holz, R. W., 1975, Biochim. Biophys. Acta 375:138–152.PubMedGoogle Scholar
  58. 58.
    Colburn, R. W., Thoa, N. B., and Kopin, I. J., 1976, Life Sci. 17:1395–1400.Google Scholar
  59. 59.
    Wonnacott, S., Marchbanks, R. M., and Fiol, C., 1978, J. Neurochem. 30:1127–1134.PubMedGoogle Scholar
  60. 60.
    Levi, G., Roberts, P. J., and Raiteri, M., 1976, Neurochem. Res. 1:409–416.Google Scholar
  61. 61.
    Vargas, O., and Orrego, F., 1976, J. Neurochem. 26:31–34.PubMedGoogle Scholar
  62. 62.
    Harris, R. A., Schmidt, J., Hitzemann, B. A., and Hitzemann, R. J., 1981, Science 212:1290–1291.PubMedGoogle Scholar
  63. 63.
    Vizi, E. S., 1978, Neuroscience 3:367–384.PubMedGoogle Scholar
  64. 64.
    O’Fallon, J. V., Brosemer, R. W., and Harding, J. W., 1981, J. Neurochem. 36:369–378.PubMedGoogle Scholar
  65. 65.
    Cheung, W. Y., 1980, Science 207:19–27.PubMedGoogle Scholar
  66. 66.
    De Lorenzo, R., 1982, Neurotransmitter Interaction and Compartmentation (H. F. Bradford, ed.), Plenum Press, New York 48:101–120.Google Scholar
  67. 67.
    Rabe, C. S., Williams, T. P., and McGee, R., 1980, Life Sci. 27:1753–1759.PubMedGoogle Scholar
  68. 68.
    Paton, D. M., 1976, The Mechanisms of Neuronal and Extraneuronal Transport of Catecholamines (D. M. Paton, ed.), Raven Press, New York, pp. 155–174.Google Scholar
  69. 69.
    Howard, B. D., and Gundersen, C. B., 1980, Annu. Rev. Pharmacol. Toxicol. 20:307–336.PubMedGoogle Scholar
  70. 70.
    Wonnacott, S., 1980, Synaptic Constituents in Health and Disease (M. Brzin, D. Sket, and H. Bachelard, eds.), Pergamon Press, Oxford, pp. 690–724.Google Scholar
  71. 71.
    Corrodi, H., and Fuxe, K., 1969, Eur. J. Pharmacol. 7:56–59.PubMedGoogle Scholar
  72. 72.
    Nielsen, M., and Braestrup, C., 1977, Naunyn-Schmiedeberg’s Arch. Pharmacol. 300:93–99.Google Scholar
  73. 73.
    Costa, E., Groppetti, A., and Naimzada, M. K., 1972, Br. J. Pharmacol. 44:742–750.PubMedGoogle Scholar
  74. 74.
    Mulder, A. H., Van der Berg, W. B., and Stoof, J. C., 1975, Brain Res. 99:419–424.PubMedGoogle Scholar
  75. 75.
    Raiteri, M., Levi, G., and Federico, R., 1974, Eur. J. Pharmacol. 28:237–240.PubMedGoogle Scholar
  76. 76.
    Thornburg, J. E., and Moore, K. E., 1973, Neuropharmacology 12:853–860.PubMedGoogle Scholar
  77. 77.
    Chiueh, C. C., and Moore, K. E., 1975, J. Pharmacol. Exp. Ther. 193:559–565.PubMedGoogle Scholar
  78. 78.
    Raiteri, M., Cerrito, F., Cervoni, A. M., del Carmine, R., Ribera, M. T., and Levi, G., 1978, Advances in Biochemical Psychopharmacology ,Volume 19, Dopamine (P. J. Roberts, G. N. Woodruff, and L. L. Iversen, eds.), Raven Press, New York, pp. 35–56.Google Scholar
  79. 79.
    Cerrito, F., Casazza, G., Levi, G., and Raiteri, M., 1980, Neurochem. Res. 5:115–121.PubMedGoogle Scholar
  80. 80.
    Hunt, P., Raynaud, J. P., Leven, M., and Schacht, U., 1979, Biochem. Pharmacol. 28:2011–2016.PubMedGoogle Scholar
  81. 81.
    Schacht, U., and Heptner, W., 1974, Biochem. Pharmacol. 23:3413–3422.PubMedGoogle Scholar
  82. 82.
    Hunt, P. P., Kannengiesser, M. H., and Raynaud, J. P., 1975, J. Pharm. Pharmacol. 26:370–371.Google Scholar
  83. 83.
    Gerhards, H. J., Carenzi, A., and Costa, E., 1974, Naunyn-Schmiedeberg’s Arch. Pharmacol. 286:49–63.Google Scholar
  84. 84.
    Samanin, R., Bernasconi, S., and Garattini, S., 1975, Eur. J. Pharmacol. 34:377–380.PubMedGoogle Scholar
  85. 85.
    Ponzio, F., Achilli, G., Perego, C., and Algen, S., 1981, Neurosci. Lett. 27:61–67.PubMedGoogle Scholar
  86. 86.
    Algeri, S., Ponzio, F., Achilli, G., and Perego, C., 1982, Typical and Atypical Antidepressants (E. Costa and G. Racagni, eds.), Raven Press, New York pp. 219–228.Google Scholar
  87. 87.
    Camanni, F., Genazzani, A. R., Massara, F., De Leo, V., Molinatti, G. M. and Muller, E. E., 1980, J. Clin. Endocrinol. Metab. 51:650–653.PubMedGoogle Scholar
  88. 88.
    Annunziato, L., Cerrito, F., and Raiteri, M., 1981, Neuropharmacology 20:727–731.PubMedGoogle Scholar
  89. 89.
    Ross, S. B., and Kelder, D., 1979, Acta Pharmacol. Toxicol. (Kbh.) 44:329–335.Google Scholar
  90. 90.
    Cerrito, F., and Raiteri, M., 1980, Eur. J. Pharmacol. 68:465–470.PubMedGoogle Scholar
  91. 91.
    Cerrito, F., Maura, G., and Raiteri, M., 1981, Apomorphine and Other Dopamine mimetics (G. L. Gessa and G. U. Corsini, eds.), Raven Press, New York, pp. 123–132.Google Scholar
  92. 92.
    Raiteri, M., Maura, G., and Cerrito, F., 1982, Typical and Atypical Antidepressants (E. Costa and G. Racagni, eds.), Raven Press, New York, pp. 199–209.Google Scholar
  93. 93.
    Maura, G., and Raiteri, M., 1982, Neurochem. Int. 4:225–231.PubMedGoogle Scholar
  94. 94.
    Braestrup, C., and Scheel-Kruger, J., 1976, Eur. J. Pharmacol. 38:305–312.PubMedGoogle Scholar
  95. 95.
    White, T. D., and Archibald, J. T., 1974, Brain Res. 82:360–364.PubMedGoogle Scholar
  96. 96.
    Raiteri, M., and Levi, G., 1973, Nature 243:180–183.Google Scholar
  97. 97.
    Raiteri, M., and Levi, G., 1973, Nature 245:89–91.Google Scholar
  98. 98.
    West, D. P., and Fillenz, M., 1980, J. Neurochem. 35:1323–1328.PubMedGoogle Scholar
  99. 99.
    Douglas, W. W., 1968, Br. J. Pharmacol. 34:451–474.PubMedGoogle Scholar
  100. 100.
    Smith, A. D., 1979, The Release of Catecholamines from Adrenergic Neurons (D. M. Paton ed.), Pergamon Press, Oxford, pp. 1–16.Google Scholar
  101. 101.
    Macintosh, F. C., 1980, Synaptic Constituents in Health and Disease (M. Brzin, D. Sket, and H. Bachelard, eds.), Pergamon Press, Oxford, pp. 11–52.Google Scholar
  102. 102.
    Tamir, H., and Rapport, M. M., 1976, Res. Commun. Chem. Pathol. Pharmacol. 13:225–235.PubMedGoogle Scholar
  103. 103.
    Halaris, A. E., and Freedman, D. X., 1977, J. Pharmacol. Exp. Ther. 203:575–586.PubMedGoogle Scholar
  104. 104.
    Kopin, I. J., Breeze, G. R., Krauss, R., and Weiss, V. K., 1968, J. Pharmacol. Exp. Ther. 161:271–278.PubMedGoogle Scholar
  105. 105.
    Besson, M. J., Cheramy, A., Feltz, P., and Glowinski, J., 1969, Proc. Natl. Acad. Sci. U.S.A. 62:741–748.PubMedGoogle Scholar
  106. 106.
    De Belleroche, J. S., Bradford, H. F., and Jones, D. G., 1976, J. Neurochem. 26:561–571.PubMedGoogle Scholar
  107. 107.
    Molenaar, P. C., Nickolson, V. J., and Polak, R. L., 1973, Br. J. Pharmacol. 47:97–108.PubMedGoogle Scholar
  108. 108.
    Weiler, M. H., Gundersen, C. B., and Jenden, D. J., 1981, J. Neurochem. 36:1802–1812.PubMedGoogle Scholar
  109. 109.
    Zimmermann, H., 1979, Neuroscience 4:1773–1804.PubMedGoogle Scholar
  110. 110.
    Whittaker, V. P., and Zimmermann, H., 1974, Synaptic Transmission and Neuronal Inter action (M. V. L. Bennett, ed.), Raven Press, New York, pp. 217–238.Google Scholar
  111. 111.
    Carroll, P. T., and Aspry, J. A. M., 1980, Science 210:641–642.PubMedGoogle Scholar
  112. 112.
    Dunant, Y., Gautron, J., Israel, M., Lesbats, B., and Manaranche, R., 1974, J. Neurochem. 23:635–643.PubMedGoogle Scholar
  113. 113.
    Marchbanks, R. M., 1975, Int. J. Biochem. 6:303–312.Google Scholar
  114. 114.
    Israel, M., Lesbats, B., and Manaranche, R., 1981, Nature 294:474–475.PubMedGoogle Scholar
  115. 115.
    Jope, R. S., 1981, J. Neurochem. 36:1712–1721.PubMedGoogle Scholar
  116. 116.
    Axelrod, J., 1973, Harvey Lect. 67:175–197.PubMedGoogle Scholar
  117. 117.
    Mennini, T., Borroni, E., Samanin, R., and Garattini, S., 1981, Neurochem. Int. 3:289–294.PubMedGoogle Scholar
  118. 118.
    Vargas, O., de Lorenzo, M. D., Saldate, M. C., and Orrego, F., 1977, J. Neurochem. 28:165–170.PubMedGoogle Scholar
  119. 119.
    de Langen, C. D. J., and Mulder, A. H., 1980, Naunyn Schmiedebergs Arch. Pharmacol. 311:169–177.PubMedGoogle Scholar
  120. 120.
    Sanders-Bush, E., and Massari, V. J., 1977, Fed. Proc. 36:2149–2153.PubMedGoogle Scholar
  121. 121.
    Fuller, R. W., 1980, Neurochem. Res. 5:241–245.PubMedGoogle Scholar
  122. 122.
    Green, A. L., and El Hait, M. A. S., 1978, J. Pharm. Pharmacol. 30:262–263.PubMedGoogle Scholar
  123. 123.
    Fuller, R. W., and Snoddy, H. D., 1979, J. Pharm. Pharmacol. 31:183–184.PubMedGoogle Scholar
  124. 124.
    Vyas, S., and Marchbanks, R. M., 1981, J. Neurochem. 37:1467–1474.PubMedGoogle Scholar
  125. 125.
    Marchbanks, R. M., Wonnacott, S., and Rubio, M. A., 1981, J. Neurochem. 36:379–393.PubMedGoogle Scholar
  126. 126.
    Langer, S. Z., 1977, Br. J. Pharmacol. 60:481–497.PubMedGoogle Scholar
  127. 127.
    Langer, S. Z., 1981, Pharmacol. Rev. 32:337–362.Google Scholar
  128. 128.
    Starke, K., 1977, Rev. Physiol. Biochem. Pharmacol. 77:1–124.PubMedGoogle Scholar
  129. 129.
    Vizi, E. S., 1979, Prog. Neurobiol. 12:181–290.PubMedGoogle Scholar
  130. 130.
    Osborne, N. N., 1981, Neurochem. Int. 3:3–16.PubMedGoogle Scholar
  131. 131.
    Hökfelt, T., Johansson, O., Ljungdahl, A., Lundberg, J. M., and Schultzberg, M., 1980, Nature 284:515–521.PubMedGoogle Scholar
  132. 132.
    Couteaux, R., and Pecot-Dechavassine, M., 1974, C. R. Acad. Sci. [D] (Paris) 278:291–293.Google Scholar
  133. 133.
    Mulder, A. H., de Langen, C. D. J., de Regt, V., and Hogenboom, F., 1978, Naunyn Schmie debergs Arch. Pharmacol. 303:193–196.Google Scholar
  134. 134.
    Stone, T. W., 1981, Neuroscience 6:523–555.PubMedGoogle Scholar
  135. 135.
    Farnebo, L. O., and Hamberger, B., 1974, J. Pharm. Pharmacol. 26:642–643.PubMedGoogle Scholar
  136. 136.
    Hamon, M., Bourgoin, S., Jagger, J., and Glowinski, J., 1974, Brain Res. 69:265–280.PubMedGoogle Scholar
  137. 137.
    Göthert, M., and Weinheimer, G., 1979, Naunyn Schmiedebergs Arch. Pharmacol. 310:93–96.PubMedGoogle Scholar
  138. 138.
    Farnebo, L. O., and Hamberger, B., 1971, Acta Physiol. Scand. [Suppl.] 371:35–44.Google Scholar
  139. 139.
    Seeman, P., and Lee, T., 1975, Science 188:1217–1219.PubMedGoogle Scholar
  140. 140.
    Dismukes, K., and Mulder, A. H., 1977, Naunyn Schmiedebergs Arch. Pharmacol. 297:23–29.PubMedGoogle Scholar
  141. 141.
    Raiteri, M., Cervoni, A. M., del Carmine, R., and Levi, G., 1978, Nature 274:706–708.PubMedGoogle Scholar
  142. 142.
    Raiteri, M., Cerrito, F., Casazza, G., and Levi, G., 1980, Advances in Biochemical Psychopharmacology ,Volume 24, Long-Term Effects ofNeuroleptics (F. Cattabeni, G. Racagni, P. F. Spano, and E. Costa, eds.), Raven Press, New York, pp. 37–43.Google Scholar
  143. 143.
    Starke, K., Reimann, W., Zumstein, A., and Hertting, G., 1978, Naunyn Schmiedebergs Arch. Pharmacol. 305:27–36.PubMedGoogle Scholar
  144. 144.
    Kamal, L. A., Arbilla, S., and Langer, S. Z., 1981, J. Pharmacol. Exp. Ther. 216:592–598.PubMedGoogle Scholar
  145. 145.
    Jackisch, R., Zumstein, A., Hertting, G., and Starke, K., 1980, Naunyn Schmiedebergs Arch. Pharmacol. 314:129–133.PubMedGoogle Scholar
  146. 146.
    Langer, S. Z., 1974, Biochem. Pharmacol. 23:1793–1800.PubMedGoogle Scholar
  147. 147.
    Seeman, P., 1980, Pharmacol. Rev. 32:229–313.PubMedGoogle Scholar
  148. 148.
    Molenaar, P. C., and Polak, R. L., 1970, Br. J. Pharmacol. 40:406–417.PubMedGoogle Scholar
  149. 149.
    Polak, R. L., 1971, Br. J. Pharmacol. 14:660–666.Google Scholar
  150. 150.
    Szerb, J. C., 1977, Cholinergic Mechanisms and Psychopharmacology (D. J. Jenden, ed.), Plenum Press, New York, pp. 49–60.Google Scholar
  151. 151.
    Rospars, J. P., Lefresne, P., Beaujouan, J. C., and Glowinski, J., 1977, Naunyn Schmiedebergs Arch. Pharmacol. 300:153–161.PubMedGoogle Scholar
  152. 152.
    Szerb, J. C., 1980, Presynaptic Receptors (S. Z. Langer, K. Starke, and M. L. Dubocovich, eds.), Pergamon Press, Oxford, pp. 293–298.Google Scholar
  153. 153.
    Raiteri, M., Marchi, M., and Paudice, P., 1981, Eur. J. Pharmacol. 74:109–110.PubMedGoogle Scholar
  154. 154.
    Schwartz, J. C., Costentin, J., Martres, M. P., Protais, P., and Baudry, M., 1978, Neuropharmacology 17:665–685.PubMedGoogle Scholar
  155. 155.
    Gnegy, M. E., and Costa, E., 1980, Essays in Neurochemistry and Neuropharmacology, Volume 4 (M. B. H. Youdim, W. Lovenberg, D. F. Sharman, and J. R. Lagnado, eds.), John Wiley & Sons, New York, pp. 249–282.Google Scholar
  156. 156.
    Reisine, T., 1981, Neuroscience 6:1471–1502.PubMedGoogle Scholar
  157. 157.
    Cerrito, F., and Raiteri, M., 1981, Eur. J. Pharmacol. 70:425–426.PubMedGoogle Scholar
  158. 158.
    Brogden, R. N., Heel, R. C., Speight, T. M., and Avery, G. S., 1978, Drugs 16:273–301.PubMedGoogle Scholar
  159. 159.
    Baumann, P. A., and Maître, L., 1977, Naunyn Schmiedebergs Arch. Pharmacol. 300:31–37.PubMedGoogle Scholar
  160. 160.
    Arbilla, S., and Langer, S. Z., 1979, Naunyn Schmiedebergs Arch. Pharmacol. 306:161–168.PubMedGoogle Scholar
  161. 161.
    Bowery, N. G., Hill, D. R., Hudson, A. L., Doble, A., Middlemiss, D. N., Shaw, J., and Turnball, M., 1980, Nature 283:92–94.PubMedGoogle Scholar
  162. 162.
    Balfour, D. J. K., 1980, Eur. J. Pharmacol. 68:11–16.PubMedGoogle Scholar
  163. 163.
    Soubrié, P., Montastruc, J. L., Bourgoin, S., Reisine, T., Artaud, F., and Glowinski, J., 1981, Eur. J. Pharmacol. 69:483–488.PubMedGoogle Scholar
  164. 164.
    Frankhuyzen, A. L., and Mulder, A. H., 1980, Eur. J. Pharmacol. 63:179–182.PubMedGoogle Scholar
  165. 165.
    Héry, F., Bourgoin, S., Hamon, M., Ternaux, J. P., and Glowinski, J., 1977, Naunyn Schmie debergs Arch. Pharmacol. 296:91–97.Google Scholar
  166. 166.
    Giorguieff-Chesselet, M. F., Kemel, M. L., Wandscheer, D., and Glowinski, J., 1979, Life Sci. 25:1257–1262.PubMedGoogle Scholar
  167. 167.
    De Belleroche, J. S., and Bradford, H. F., 1978, Brain Res. 142:53–68.PubMedGoogle Scholar
  168. 168.
    Giorguieff-Chesselet, M. F., Kemel, M. L., and Glowinski, J., 1979, Neurosci. Lett. 14:177–182.PubMedGoogle Scholar
  169. 169.
    Ennis, C., Kemp, J. D., and Cox, B., 1981, J. Neurochem. 36:1515–1520.PubMedGoogle Scholar
  170. 170.
    Stoof, J. C., and Mulder, A. H., 1977, Eur. J. Pharmacol. 46:177–180.PubMedGoogle Scholar
  171. 171.
    Starr, M. S., 1979, Eur. J. Pharmacol. 53:215–226.PubMedGoogle Scholar
  172. 172.
    Giorguieff, M. F., Kemel, M. L., Glowinski, J., and Besson, M. J., 1978, Brain Res. 139:115–130.PubMedGoogle Scholar
  173. 173.
    Ennis, C., and Cox, B., 1981, Eur. J. Pharmacol. 70:417–420.PubMedGoogle Scholar
  174. 174.
    Giorguieff-Chesselet, M. F., Besson, M. J., Cheramy, A., and Glowinski, J., 1979, J. Physiol. (Paris) 75:611–613.Google Scholar
  175. 175.
    Giorguieff-Chesselet, M. F., Kemel, M. L., Wandsheer, D., and Glowsinki, J., 1979, Eur. J. Pharmacol. 60:101–104.Google Scholar
  176. 176.
    Roberts, P. J., and Anderson, S. D., 1979, J. Neurochem. 32:1539–1545.PubMedGoogle Scholar
  177. 177.
    Stoof, J. C., Den Breejen, E. J. S., and Mulder, A. H., 1979, Eur. J. Pharmacol. 57:35–42.PubMedGoogle Scholar
  178. 178.
    Scatton, B., and Bartholini, G., 1981, Cholinergic Mechanisms: Phylogenetic Aspects, Central and Peripheral Synapses, and Clinical Significance (G. Pepeu and H. Ladinsky, eds.), Plenum Press, New York, pp. 771–780.Google Scholar
  179. 179.
    Ladinsky, H., Consolo, S., Bianchi, S., and Jori, H., 1976, Brain Res. 108:351–361.PubMedGoogle Scholar
  180. 180.
    Beani, L., Bianchi, C., and Tanganelli, S., 1981, Cholinergic Mechanisms: Phylogenetic As pects, Central and Peripheral Synapses, and Clinical Significance (G. Pepeu and H. Ladinsky, eds.), Plenum Press, New York, pp. 763–770.Google Scholar
  181. 181.
    Bianchi, C., Tanganelli, S., Marzola, G., and Beani, L., 1982, Naunyn Schmiedebergs Arch. Pharmacol. 318:253–258.PubMedGoogle Scholar
  182. 182.
    Vizi, E. S., Hársing, L. G., and Knoll, J., 1977, Neuroscience 2:953–961.Google Scholar
  183. 183.
    Miller, J. C., and Friedhoss, A. J., 1979, Life Sci. 25:1249–1256.PubMedGoogle Scholar
  184. 184.
    Bianchi, C., Tanganelli, S., and Beani, L., 1979, Eur. J. Pharmacol. 58:235–246.PubMedGoogle Scholar
  185. 185.
    Hertting, G., Zumstein, A., Jackisch, R., Hoffmann, I., and Starke, K., 1980, Naunyn Schmie debergs Arch. Pharmacol. 315:111–117.Google Scholar
  186. 186.
    Beani, L., Bianchi, C., Giacomelli, A., and Tamberi, F., 1978, Eur. J. Pharmacol. 48:179–193.PubMedGoogle Scholar
  187. 187.
    Vizi, E. S., Ronai, A., Harsing, L. G., Jr., and Knoll, J., 1977, Cholinergic Mechanisms and Psychopharmacology (D. J. Jenden, ed.), Plenum Press, New York, pp. 587–603.Google Scholar
  188. 188.
    Vizi, E. S., 1980, Neuroscience 5:2139–2144.PubMedGoogle Scholar
  189. 189.
    Euvrard, C., Javoy, F., Herbet, A., and Glowinski, J., 1977, Eur. J. Pharmacol. 41:281–289.PubMedGoogle Scholar
  190. 190.
    Ladinsky, H., Consolo, S., Peri, G., Crunelli, V., and Samanin, R., 1977, Cholinergic Mechanisms and Psychopharmacology (D. J. Jenden, ed.), Plenum Press, New York, pp. 615–627.Google Scholar
  191. 191.
    Pull, I., and Mcllwain, H., 1972, Biochem. J. 126:965–970.PubMedGoogle Scholar
  192. 192.
    Daval, J. L., Barberis, C., and Gayet, J., 1980, Brain Res. 181:161–168.PubMedGoogle Scholar
  193. 193.
    Harms, H. H., Wardeh, G., and Mulder, A. H., 1979, Neuropharmacology 18:577–582.PubMedGoogle Scholar
  194. 194.
    Harms, H. H., Wardeh, G., and Mulder, A. H., 1978, Eur. J. Pharmacol. 49:305–400.PubMedGoogle Scholar
  195. 195.
    Hollins, C., and Stone, T. W., 1980, J. Physiol. (Lond.) 303:73–78.Google Scholar
  196. 196.
    Ribeiro, J. A., Sa-Almeida, A. M., and Namorado, J. M., 1979, Biochem. Pharmacol. 28:1297–1300.PubMedGoogle Scholar
  197. 197.
    Michaelis, M. L., Michaelis, E. K., and Myers, S. L., 1979, Life Sci. 24:2083–2092.PubMedGoogle Scholar
  198. 198.
    Barberis, C., Minn, A., and Gayet, J., 1981, J. Neurochem. 36:347–354.PubMedGoogle Scholar
  199. 199.
    Corrieri, A. G., Barberis, C., and Gayet, J., 1981, Biochem. Pharmacol. 30:2732–2734.PubMedGoogle Scholar
  200. 200.
    Göthert, M., 1979, Naunyn Schmiedebergs Arch. Pharmacol. 307:29–37.PubMedGoogle Scholar
  201. 201.
    Göthert, M., 1980, Naunyn Schmiedebergs Arch. Pharmacol. 314:223–230.PubMedGoogle Scholar
  202. 202.
    Nordström, O., and Bartfai, T., 1981, Brain Res. 213:467–471.PubMedGoogle Scholar
  203. 203.
    Ichida, S., Osugi, T., Noguchi, Y., and Yoshida, H., 1981, Brain Res. 213:472–475.PubMedGoogle Scholar
  204. 204.
    Dismukes, R. K., and Mulder, A. H., 1976, Eur. J. Pharmacol. 39:383–388.PubMedGoogle Scholar
  205. 205.
    Powis, D. A., 1981, Biochem. Pharmacol. 30:2389–2397.PubMedGoogle Scholar
  206. 206.
    De Belleroche, J. S., and Bradford, H. F., 1973, Prog. Neurobiol. 1:275–298.Google Scholar
  207. 207.
    Levi, G., Gallo, V., Ciotti, T., and Raiteri, M., 1979, J. Neurochem. 33:1043–1053.Google Scholar
  208. 208.
    Redburn, D. A., Broome, D., Ferkany, J., and Enna, S. J., 1978, Brain Res. 152:511–519.PubMedGoogle Scholar
  209. 209.
    Nomura, Y., Yotsumoto, I., and Segawa, T., 1981, Dev. Brain Res. 1:171–177.Google Scholar
  210. 210.
    Bourgoin, S., Artaud, F., Enjalbert, A., Héry, F., Glowinski, J., and Hamon, M., 1977, J. Pharmacol. Exp. Ther. 202:519–531.PubMedGoogle Scholar
  211. 211.
    Werner, J., and Mulder, A. H., 1981, Brain Res. 208:299–309.Google Scholar
  212. 212.
    Marchi, M., Hoffman, D. W., Giacobini, E., and Volle, R., 1981, Dev. Neurosci. 4:442–450.PubMedGoogle Scholar
  213. 213.
    Gibson, G. E., and Peterson, C., 1981, J. Neurochem. 37:978–984.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1984

Authors and Affiliations

  • Maurizio Raiteri
    • 1
  • Mario Marchi
    • 1
  • Guido Maura
    • 1
  1. 1.Istituto di Farmacologia e FarmacognosiaUniversità di GenovaGenoaItaly

Personalised recommendations